EWA
ELDN icon

EverSource Wealth Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

EverSource Wealth Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68K Buy
1,443
+537
+59% +$1.95K ﹤0.01% 3224
2026
Q1 		$2.79K Buy
906
+557
+160% +$1.31K ﹤0.01% 3517
2025
Q4 		$527 Buy
+349
New +$830 ﹤0.01% 3865

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

EverSource Wealth Advisors's ELDN Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Eledon Pharmaceuticals (ELDN) stake by 59% in Q2 2026, buying an estimated $1.95K and bringing the position to 1,443 shares worth $5.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3224.

EverSource Wealth Advisors first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • EverSource Wealth Advisors held 1,443 shares of Eledon Pharmaceuticals worth $5.68K as of Q2 2026.
  • EverSource Wealth Advisors bought 537 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.95K.
  • Eledon Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3224 holding.
  • EverSource Wealth Advisors first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.